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Butter increases HDL functional capacity: is this compensation for its adverse effect on serum LDL-
cholesterol? 
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Controversy over the dietary guidelines to reduce saturated fatty acids (SFA) rests heavily on the lack 
of evidence from meta-analyses for a direct association between dietary SFA and lower CVD 
mortality1.2. Evidence that a lower intake of SFA reduces CVD events has been reported, and can be 
explained, in part, by the lowering of serum LDL-cholesterol2, a causal risk factor for the 
development of CVD3. Somewhat counter intuitively, the effects of SFA on the putatively beneficial 
serum HDL-cholesterol run in parallel to that of LDL-cholesterol, but how these diet-induced changes 
in HDL-cholesterol impact on CVD risk, is less clear.  
The effects of dietary SFA on serum LDL-cholesterol depend on what macronutrient (unsaturated 
fatty acids and/or carbohydrate) replaces the SFA4, and other constituents in the food, including its 
specific SFA content, and other components of the food matrix, such as protein, minerals, fiber5. The 
study by Brassard et al6, examines these phenomena in relation to HDL-cholesterol, but extends its 
analysis to the substructure and function of HDL with relevance to the potential cardio-protective 
role of this lipoprotein.   
A strong inverse association exists between serum HDL-cholesterol and CVD risk in populations, and 
underlies the diagnostic value of low serum HDL-cholesterol and the total cholesterol to HDL-
cholesterol ratio as a discriminating marker of CVD risk7. In comparison, there is relatively little 
evidence that raising low serum HDL cholesterol decreases CVD risk. There is increasing evidence to 
suggest that the measurement of the amount of cholesterol in HDL may be inadequate as a 
biomarker of CVD risk8. HDL is a vehicle for the extracellular transport of cholesterol from peripheral 
tissues to the liver, a process known as reverse cholesterol transport. While difficult to measure 
directly in vivo, this process can be assessed as the capacity of HDL taken from participants, ex-vivo, 
to perform efflux of radiolabelled cholesterol from cultured cells.    
The study by Brassard et al6, is a secondary analysis of a randomly controlled intervention trial9 that 
confirmed earlier reports that equivalent amounts of SFA from cheese had a lesser effect in 
elevating serum LDL-cholesterol than butter10,11. This was attributed to a food matrix effect of cheese 
that was proposed to reduce the absorption of SFA in the gut, and thus its capacity to raise LDL 
cholesterol. This so-called ‘cheese-matrix’ effect may originate from a combination of factors, 
involving the composition of fat, protein or calcium in cheese, and/or its effects upon the 
microbiome and fermentation in the gut5. The first paper on this study, examined four test diets, 
each of 4 weeks, in a total of 92 abdominally obese men and women, in a randomly controlled cross-
over design9.  Two of the diets were rich in SFA (12.4-12.6%E) from butter and cheese, while the 
other diets replaced SFA (5.8%E) with either monounsaturated fat from olive oil or polyunsaturated 
fat from corn oil. The test diets were compared with a low fat (5.8%E SFA, 25%E total fat) high 
carbohydrate (59%E) control. In the present study6, the principal outcome was HDL-mediated 
cholesterol efflux capacity (CEC), as measured by the capacity of apo B free serum from 46 
participants to remove radiolabelled cholesterol (3H-cholesterol) from J774 macrophages cultured 
under basal conditions. A secondary outcome included the distribution of serum HDL subclasses 
known to be involved in cholesterol efflux, and thus informative with respect to CEC.   
The butter and MUFA-rich diets increased CEC relative to cheese (4.3% and 4.7%, respectively). The 
effects of butter were significant in men (+6%), but not women, and for MUFA, significant in women, 
but not men. The differential effects of butter and cheese diets on the distribution of serum HDL 
subclasses were complex, but interpreted to be consistent with CEC being attenuated on the cheese 
relative to butter diet. Contrary to the findings in the first paper of this study9, the relative increase 
in serum LDL cholesterol in butter versus cheese diets did not reach statistical significance in this 
secondary analysis, presumably because of the smaller subgroup of participants. The relative effects 
of butter over cheese on CEC are concluded to arise from the higher circulating LDL or oxysterols 
derived from LDL. This possibility is further supported by a significant correlation between the 
change in serum LDL-cholesterol in men, but not women.  
These findings provide new evidence to show that increased HDL-cholesterol, but more critically 
increased HDL-mediated CEC, induced by SFA in butter, may arise as compensation for the increase 
in LDL-cholesterol. Whether this compensation exerts an overall benefit on CVD risk is unknown, and 
may ultimately depend on the extent to which it counteracts the adverse impact of butter in raising 
LDL-cholesterol. In contrast, the significant increase in HDL-mediated CEC in women after the MUFA-
rich diet could be interpreted as being of greater benefit in reducing CVD risk, since this diet lowered 
serum LDL cholesterol relative to butter and cheese. Another interesting aspect of this study is 
whether the men and women had any characteristics that could explain why they were more 
responsive to SFA in butter and MUFA, respectively.  This raises the important question; does the 
extent of compensation vary between different individuals, and if so, what are the determinants of 
this variability?  
This study of Brassard et al6, provides new insight into the extent of the cheese-matrix effect on HDL 
function, further highlighting the importance of the nature of SFA-rich foods in the management of 
CVD risk. The adverse effect of SFA in butter in raising serum LDL-cholesterol is well established. 
Whether increased HDL-mediated CEC compensates for this effect in any way is unclear, and will 
require confirmation in large human intervention studies with this, and other measures of HDL 
function.  
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